Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir–rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study

作者：Aditya H Gaur, Kristin Baltrusaitis, E. Capparelli, John H Moye, Dwight E Yin, Gaerolwe Masheto, Sarah Buisson, Conn Harrington, Mark A. Marzinke, Elizabeth D. Lowenthal, Rachel Scheckter, Andi Ace, S. M. Ward, Ryan Milligan, Kyle Whitson, Jenny Huang, S Y Amy Cheung, Brookie M. Best, Ellen Townley, Gilly Roberts, Thomas N. Kakuda, Eileen Birmingham, Sisinyana Ruth Mathiba, Linda Aurpibul, Violet Korutaro, C. Estelle Smith, Faeezah Patel, Evette Moodley, Carolyn Bolton-Moore, Allison L Agwu, Avy Violari, Pradthana Ounchanum, Maxensia Owor, Kulkanya Chokephaibulkit, Andres Camacho-Gonzalez, Mary Paul, Samantha Fry, Jennifer Jao, Charles D Mitchell, Sara Zabih, Rodica M Van Solingen-Ristea, Anna Dari, Herta Crauwels, Veerle Van Eygen, Kati Vandermeulen, Ann M Buchanan, Yu-Wei Lin, Isabelle Déprez, Kelong Han, Susan L. Ford, Jon Collins, Barbara Heckman, Chelsea Stotz · 发表于：The Lancet HIV · 年份：2026 · DOI：10.1016/s2352-3018(25)00242-5 · 被引用次数：3 · 研究领域：HIV/AIDS drug development and treatment、HIV-related health complications and treatments、Virus-based gene therapy research